The global sclerotherapy market size was valued at USD 848.8 million in 2019 and is anticipated to grow at a CAGR of 5.6% from 2021 to 2028. Growing geriatric population, rising incidence of varicose veins, technological advancements pertaining to venous diseases, and growing demand for minimally invasive procedures are driving the market. Introduction of ultrasound-guided sclerotherapy and foam sclerotherapy has enabled practitioners to carry out these procedures in the underlying veins with precision and care.
Sclerotherapy is a minimally invasive procedure used for the treatment of spider veins or varicose veins and involves injecting the veins with sclerosing agents like detergents, chemicals, and osmotic agents. It causes shrinking of the veins and reduces the damage.
Market Trends, Drivers, Restraints, and Opportunities:
- Growing prevalence of thrombotic disorders leads to stroke or mesenteric ischemia, which drives the sclerotherapy market.
- Recent advancements in cardiology such as revascularization and cardiogenic shock is likely to boost the sclerotherapy market.
- Rising incidence of varicose veins drives the sclerotherapy market.
- Complications in dermatological procedures such as bleeding and infection increases pain and discomfort and delays the healing process. This factor is likely to hamper the growth of the sclerotherapy market.
- Treatment may cause matting, scarring, and allergic reactions in some patients, which might hinder the market growth.
- Advent of advanced treatment options for varicose veins such as endovenous laser ablation, radiofrequency ablation, conventional operation, and subfascial endoscopic perforator surgery are expected to hinder the market growth.
- Technical advancement in the field of sclerotherapy such as cryotherapy, which delivers cold air into the skin leading to a pain-free process, acts as an opportunity for the sclerotherapy market.
Scope of Sclerotherapy Market Report
The report on acupuncture needles market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have been included in the report.
Attributes
|
Details
|
Report Title
|
Sclerotherapy Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2020
|
Historic Data
|
2018-2019
|
Forecast Period
|
2021-2028
|
Segmentation
|
Agents (Detergents, Chemical Irritants, and Osmotic Agents), Types (Ultrasound Sclerotherapy, Liquid Sclerotherapy, and Foam Sclerotherapy), Applications (Venous Disease, Gastrointestinal Bleeding, Bronchopleural Fistula, Cystic Disease, Systemic Diseases)
|
Regional Scope
|
Asia Pacific, North America, Europe, Latin America, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players
|
Boston Scientific Corporation, Chemische Fabrik Kreussler & Co. GmbH, LGM Pharma, TIANYU CHANG’AN GROUP, and AngioDynamics.
|
Sclerotherapy Market Segment Insights:
Detergents Segment held a substantial market share during the forecast period
Based on agents, the sclerotherapy market is fragmented into detergents, chemical irritants, and osmotic agents. The detergents segment held a substantial market share of 42.0% in 2019 and is expected to witness a high CAGR during the forecast period. Detergents sclerosing agents are used to treat spider telangiectasias in various concentrations ranging from 0.05% to 0.5%. Detergents work by a mechanism known as protein theft denaturation, which causes endothelial damage or desquamation of endothelial cells in plaques through interference with cell surface lipids. Common types of detergents are Sodium Morrhuate (SM), Ethanolamine Oleate (EO), Sodium Tetradecyl Sulphate (Sotradecol), Polidocanol, and Scleremo.
Liquid Sclerotherapy is Expected to Occupy a Significant Share over the Forecast Period
On the basis of types, the sclerotherapy market is segmented into ultrasound sclerotherapy, liquid sclerotherapy, and foam sclerotherapy. The liquid sclerotherapy segment held a high market share of 38.0% in 2019 and is anticipated to witness a significant CAGR during the forecast period. Foam sclerotherapy is based on the air-block technique, wherein a small bubble of air is injected into the target vessel and the sclerosant is injected in the center of the bubble.
A foam with detergent sclerosants allows efficient sclerosant effect by increasing both contact area and dwell time and minimizing the admixture of sclerosant and blood. Increasing efficiency allows low sclerosants doses. Ultrasound-guided foam sclerotherapy is an upcoming therapy, which allows doctors to monitor the effect of each injection while ensuring the safety of all adjacent structures. It is effective as compared to a liquid therapy.
North America is Expected to Dominate the Sclerotherapy Myomectomy Market Over the Forecast Period
On the basis of regions, the sclerotherapy market is split into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America is dominating the market and accounts for a revenue share of 46.1% in 2019. The market in North America is expected to witness a significant CAGR during the forecast period, due to increasing R&D investments and presence of global players. As per the Society of Vascular Surgery, more than 33.0% of women and about 17.0% of men consulted a doctor for telangiectasias and varicose veins in industrialized countries, affecting up to 35.0% of people in the US and Europe.
Segments
By Agents
- Detergents
- Chemical Irritants
- Osmotic Agents
By Types
- Ultrasound Sclerotherapy
- Liquid Sclerotherapy
- Foam Sclerotherapy
By Application type
- Venous Disease
- Gastrointestinal Bleeding
- Bronchopleural Fistula
- Cystic Disease
- Systemic Diseases
By Regions
- Asia Pacific
- North America
- Europe
- Latin America
- Middle East & Africa
Key Players
Competitive Landscape
Key players in the sclerotherapy market include Boston Scientific Corporation, Chemische Fabrik Kreussler & Co. GmbH, LGM Pharma, TIANYU CHANG’AN GROUP, and AngioDynamics. For instance, in March 2016, Merz Pharma and AngioDynamics, which produce innovative and minimally invasive medical devices for vascular access, surgery, and peripheral vascular disease, signed an agreement.